SLS
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- SELLAS Life Sciences enrolled the first patient in its frontline AML trial evaluating SLS009Mar 12, 2026
- SELLAS Life Sciences entered agreement with IMPACT-AML to expand SLS009 program into EuropeJan 14, 2026
- SELLAS provides update on Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemiaDec 29, 2025
- SELLAS meets all primary endpoints in Phase 2 trial of SLS009 in relapsed/refractory AML and receives FDA guidance to advance into first-line therapy studyJul 15, 2025
- SELLAS Life Sciences announces first pediatric AML patient dosed in the ongoing Phase 2 trial of SLS009 r/r AML.May 15, 2025